Abstract Enolase 1 (Eno1p) of Candida albicans is an immunodominant antigen. However,
conventional technologies for preparing an injectable vaccine require purification of the
antigenic protein and preparation of an adjuvant. To develop a novel type of oral vaccine
against candidiasis, we generated Saccharomyces cerevisiae cells that display the Eno1p
antigen on their surfaces. Oral delivery of the engineered S. cerevisiae cells prolonged
survival rate of mice that were subsequently challenged with C. albicans. Given that a …